CommercialCoverageMedium impact
Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia
Blue Cross & Blue Shield of Mississippi·MS · Urology·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield has classified the iTind temporarily implanted nitinol device for treating benign prostatic hyperplasia (BPH) as investigational, meaning it is not covered. New CPT codes 53865 and 53866 are effective January 1, 2025, but claims using these codes will be denied as investigational.
Action Required
By January 1, 2025: Billing team must update system to flag CPT codes 53865 and 53866 as investigational/non-covered for BCBS plans. Update encounter forms to alert providers that iTind procedures are not covered. Claims submitted with these codes will be denied unless patient has signed ABN for investigational services.